Company RenovoRx, which develops a honey device to heal decent tumors, attracted 17 million dollars, releasing 1,85 million packages of 9 Dollars, low cost of the revised spectrum from 9 to 11 Dollars. Each package consists of one ordinary share and 1 order, due on 10,80 Dollars.
Initially, the company applied for the issue of shares at a value of 12 to 14 Dollars, but after twice reduced the declared spectrum. Taking into account the real IPO price, the full diluted market price of RenovoRx will be about 115 million dollars.
RenovoRx планирует листинг обычных акций на бирже Nasdaq under the ticker RNXT. The only organizer of the issue of shares was Roth Capital.
